301 related articles for article (PubMed ID: 34142863)
1. Health Claims About Cannabidiol Products: A Retrospective Analysis of U.S. Food and Drug Administration Warning Letters from 2015 to 2019.
Wagoner KG; Lazard AJ; Romero-Sandoval EA; Reboussin BA
Cannabis Cannabinoid Res; 2021 Dec; 6(6):559-563. PubMed ID: 34142863
[No Abstract] [Full Text] [Related]
2. Unsubstantiated health claims for COVID-19 infections are led by cannabidiol: return of snake oil medicine.
Tran A; Sheikhan NY; Sheikhan T; Nowak DA; Witek TJ
J Cannabis Res; 2021 Dec; 3(1):49. PubMed ID: 34876238
[TBL] [Abstract][Full Text] [Related]
3. CBD Retailers in NC Promote CBD Online to Treat Pain Violating FDA Rules About Medical Claims and Offer Low-CBD/High-Price Products.
Amann L; Kruse E; Lazard AJ; Reboussin BA; Wagoner KG; Romero-Sandoval EA
J Pain Res; 2022; 15():3847-3858. PubMed ID: 36514481
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Claims in Cannabidiol (CBD) Marketing Messages on Twitter.
Soleymanpour M; Saderholm S; Kavuluru R
Proceedings (IEEE Int Conf Bioinformatics Biomed); 2021 Dec; 2021():3083-3088. PubMed ID: 35096472
[TBL] [Abstract][Full Text] [Related]
5. Violation of US regulations regarding online marketing and sale of e-cigarettes: FDA warnings and retailer responses.
Nguyen H; Dennehy CE; Tsourounis C
Tob Control; 2020 Dec; 29(e1):e4-e9. PubMed ID: 32123138
[TBL] [Abstract][Full Text] [Related]
6. Analysis of US Food and Drug Administration Warning Letters: False Promotional Claims Relating to Prescription and Over-the-Counter Medications.
Salas M; Martin M; Pisu M; McCall E; Zuluaga A; Glasser SP
Pharmaceut Med; 2008 Mar; 22(2):. PubMed ID: 24353430
[TBL] [Abstract][Full Text] [Related]
7. Cannabidiol (CBD) in Dietary Supplements: Perspectives on Science, Safety, and Potential Regulatory Approaches.
Walker LA; Koturbash I; Kingston R; ElSohly MA; Yates CR; Gurley BJ; Khan I
J Diet Suppl; 2020; 17(5):493-502. PubMed ID: 32543246
[TBL] [Abstract][Full Text] [Related]
8. Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated With US Food and Drug Administration Warnings.
Tucker J; Fischer T; Upjohn L; Mazzera D; Kumar M
JAMA Netw Open; 2018 Oct; 1(6):e183337. PubMed ID: 30646238
[TBL] [Abstract][Full Text] [Related]
9. An analysis of the warning letters issued by the FDA to pharmaceutical manufacturers regarding misleading health outcomes claims.
Chatterjee S; Patel HK; Sansgiry SS
Pharm Pract (Granada); 2012 Oct; 10(4):194-8. PubMed ID: 24155837
[TBL] [Abstract][Full Text] [Related]
10. FDA actions against health economic promotions, 2002-2011.
Neumann PJ; Bliss SK
Value Health; 2012; 15(6):948-53. PubMed ID: 22999146
[TBL] [Abstract][Full Text] [Related]
11. Debunking Cannabidiol as a Treatment for COVID-19: Time for the FDA to Adopt a Focused Deterrence Model?
Shover CL; Humphreys K
Cureus; 2020 Jun; 12(6):e8671. PubMed ID: 32699671
[TBL] [Abstract][Full Text] [Related]
12. Labeling of Cannabidiol Products: A Public Health Perspective.
Corroon J; MacKay D; Dolphin W
Cannabis Cannabinoid Res; 2020; 5(4):274-278. PubMed ID: 33381640
[No Abstract] [Full Text] [Related]
13. Unicorn Poo and Blessed Waters: COVID-19 Quackery and FDA Warning Letters.
Bramstedt KA
Ther Innov Regul Sci; 2021 Jan; 55(1):239-244. PubMed ID: 33001378
[TBL] [Abstract][Full Text] [Related]
14. Selling cannabidiol products in Canada: A framing analysis of advertising claims by online retailers.
Zenone MA; Snyder J; Crooks V
BMC Public Health; 2021 Jul; 21(1):1285. PubMed ID: 34210299
[TBL] [Abstract][Full Text] [Related]
15. FDA actions against misleading or unsubstantiated economic and quality-of-life promotional claims: an analysis of warning letters and notices of violation.
Stewart KA; Neumann PJ
Value Health; 2002; 5(5):390-7. PubMed ID: 12201856
[TBL] [Abstract][Full Text] [Related]
16. Over-the-Counter Drugs: Regulatory Analysis of Warning Letters Between Fiscal Years 2015-2019.
Bai HK; Ahearn JD; Bartlett MG
Ther Innov Regul Sci; 2021 Mar; 55(2):426-436. PubMed ID: 33095420
[TBL] [Abstract][Full Text] [Related]
17. Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters.
Kim H
Int J Health Policy Manag; 2015 Aug; 4(12):813-21. PubMed ID: 26673465
[TBL] [Abstract][Full Text] [Related]
18. Cannabidiol and Other Cannabinoids: From Toxicology and Pharmacology to the Development of a Regulatory Pathway.
Koturbash I; MacKay D
J Diet Suppl; 2020; 17(5):487-492. PubMed ID: 32715797
[TBL] [Abstract][Full Text] [Related]
19. Single Cigarette Sales: State Differences in FDA Advertising and Labeling Violations, 2014, United States.
Baker HM; Lee JG; Ranney LM; Goldstein AO
Nicotine Tob Res; 2016 Feb; 18(2):221-6. PubMed ID: 25744967
[TBL] [Abstract][Full Text] [Related]
20. A review of FDA warning letters and notices of violation issued for patient-reported outcomes promotional claims between 2006 and 2012.
Symonds T; Hackford C; Abraham L
Value Health; 2014 Jun; 17(4):433-7. PubMed ID: 24969004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
